The estimated Net Worth of Daniel Horwood is at least $31.1 millier dollars as of 3 August 2020. Daniel Horwood owns over 10,000 units of Catheter Precision stock worth over $31,058 and over the last 6 years Daniel sold RMED stock worth over $0.
Sign up
Daniel Horwood RMED stock SEC Form 4 insiders trading
Daniel has made over 2 trades of the Catheter Precision stock since 2020, according to the Form 4 filled with the SEC. Most recently Daniel bought 10,000 units of RMED stock worth $3,500 on 3 August 2020.
The largest trade Daniel's ever made was buying 10,000 units of Catheter Precision stock on 3 August 2020 worth over $3,500. On average, Daniel trades about 2,857 units every 10 days since 2018. As of 3 August 2020 Daniel still owns at least 52,641 units of Catheter Precision stock.
You can see the complete history of Daniel Horwood stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Daniel Horwood's mailing address?
Daniel's mailing address filed with the SEC is C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DR., CARLSBAD, CA, 92011.
Insiders trading at Catheter Precision
Over the last 6 years, insiders at Catheter Precision have traded over $709,539 worth of Catheter Precision stock and bought 199,373 units worth $197,741 . The most active insiders traders include Jeffrey J Kraws, Jonathan Will Mc Guire et Dean Burstein Melissa Dean .... On average, Catheter Precision executives and independent directors trade stock every 34 days with the average trade being worth of $12,983. The most recent stock trade was executed by Andrew C. Jackson on 20 November 2021, trading 2,684 units of RMED stock currently worth $7,032.
What does Catheter Precision do?
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
What does Catheter Precision's logo look like?
Complete history of Daniel Horwood stock trades at Catheter Precision
Catheter Precision executives and stock owners
Catheter Precision executives and other stock owners filed with the SEC include:
-
Jonathan Will McGuire,
CEO & Director -
Andrew C. Jackson,
Chief Financial Officer -
Brian D. Conn,
Interim CFO, Principal Financial Officer & Principal Accounting Officer -
Al Memmolo B.S. MBA,
Sr. VP of Clinical, Quality & Regulatory Affairs -
Maria Villanueva,
VP & Compliance Officer -
Tiah Reppas,
VP, Chief Accounting Officer & Corp. Controller -
James Joseph Caruso,
-
Dean Dean Irwin & Melissa B...,
See Remarks -
Joan Stafslien,
Director -
Martin Martin Burstein Livi...,
-
William R Enquist,
Director -
Maurice Buchbinder,
Director -
Daniel Horwood,
General Counsel -
Richard Jr Mejia,
Director -
Martin J Colombatto,
Director -
Mark E Saad,
Director -
Dean Burstein Melissa Dean ...,
-
Thomas G Fogarty,
See Remarks -
Jeffrey J Kraws,
Co-President -
David A Jenkins,
Ex. Chairman of the Board -
Andrew C. Jackson,
CFO -
Dean Irwin,
10% owner -
Susanne Meline,
-
Jonathan Will Mc Guire,
CEO & Secretary